◀ Back to PRKAG1
G6PC — PRKAG1
Pathways - manually collected, often from reviews:
Text-mined interactions from Literome
Mues et al., Horm Metab Res 2009
(Diabetes Mellitus, Type 2) :
These data indicate a differential
AMPK dependent regulation of
G6Pase gene expression by insulin and metformin under basal and dexamethasone/cAMP stimulated conditions
Ota et al., Biochem Biophys Res Commun 2009
:
Both metformin and rotenone, an inhibitor of respiratory chain complex I, suppressed glucose-6-phosphatase (
G6pc ), a rate limiting enzyme of liver glucose production, mRNA expression in a rat hepatoma cell line accompanied by a reduction of intracellular ATP concentration and an
activation of
AMP activated protein kinase (AMPK)
Lee et al., J Biol Chem 2010
:
In addition, metformin or overexpression of a constitutively active form of
AMPK ( Ad-CA-AMPK )
inhibited S171A mediated PEPCK and
G6Pase gene expression, and hepatic glucose production and knockdown of SHP partially relieved the metformin- and Ad-CA-AMPK mediated repression of hepatic gluconeogenic enzyme gene expression in primary rat hepatocytes
Singhal et al., PloS one 2011
(Metabolic Syndrome X) :
The ultimate effectors of gluconeogenesis are the three enzymes : PEPCK, F-1,6-BPase, and
G6Pase , and their expression is
regulated by PPAR? and
AMPK